These factors are currently under intense focus in the cancer immunotherapy landscape. Missing the target in cancer therapy | Nature Cancer ImmunoMet Therapeutics is a biopharmaceutical company that develops and commercializes oncology products for cancer patients. ImmunoMet Therapeutics is a development-stage biopharmaceutical company focused on the development and commercialization of novel oncology products . Individuals who thrive in our environment are team-oriented, self-motivated, creative, and persistent. While induction of tumor-reactive CD8+ T cells is a major goal of cancer therapy, CD4+ T cells provide essential support to CD8+ T cells by promoting their expression of cytotoxic effector molecules and increasing their migratory capacity. Immunomic Therapeutics' nucleic acid vaccines have the . Previously, Ms. Harrison served as Senior Vice President, Global Regulatory Affairs and Compliance at BTG International (now Boston Scientific). MiNA Therapeutics Limited Translation & Innovation Hub 84 Wood Lane London W12 0BZ United Kingdom. With HLBs support, we are well-positioned to accelerate our efforts in immuno-oncology, in particular glioblastoma multiforme, and rapidly advance other key candidates in our pipeline, including our most recent initiative into infectious diseases with development of our vaccine candidate for COVID-19.. News | Astellas Pharma Inc. Recruiters: We do not accept unsolicited resumes from any source other than directly from the candidate. Immunomic Therapeutics Strengthens Leadership Team with Appointment of Additionally, our expanded capabilities allow us to work with our corporate partners to better understand and develop the manufacturing process and product testing assays. Active, Closed, Last funding round type (e.g. Immunomic Therapeutics, Inc. is committed to building, developing and retaining a world-class team. UNITE is currently being employed in Phase II clinical trials as a cancer immunotherapy. Immunomic Therapeutics, Inc. announced today that it has assumed sponsorship of the Investigational New Drug (IND) application for ITI-1000 from the University of Florida (UF). Clin Cancer Res 2020;26:5297303, Batich K.A.,Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination. Immunomic Therapeutics - Products, Competitors, Financials, Employees ITI believes that these early clinical studies may provide a proof of concept for UNITE therapy in cancer, and if successful, set the stage for future studies, including combinations in these tumor types and others. Immunomic Therapeutics Receives FDA Fast Track Designation for ITI-3000, a pDNA Vaccine, in Development for the Treatment of Merkel Cell Carcinoma November 08, 2022 08:30 AM Eastern Standard Time 717-327-1822, ITI Media: Companies - Johns Hopkins Technology Ventures Work Here? Curr Opin Immunol. AAPL, FB, TWTR), Total amount raised across all funding rounds, Total number of Crunchbase contacts associated with this organization, Total number of employee profiles an organization has on Crunchbase, Total number of investment firms and individual investors, Descriptive keyword for an Organization (e.g. Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company revolutionizing the study of the Lysosomal Associated Membrane . We are pleased to welcome HLB as a significant shareholder of Immunomic Therapeutics and look forward to working with them within the framework of the HLB Bio family of companies. For more information, please visit www.immunomix.com. Immunomic Therapeutics Company Profile: Valuation & Investors | PitchBook San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. Developer of lysosomal-associated membrane protein (LAMP)-based vaccines designed to use immunotherapy to treat cancer, allergies, and animal health. This is the Immunomic Therapeutics company profile. Phone Number +4989208047700. Sampson and Mitchell in the development of a new approach to attack Glioblastoma Multiforme (GBM). Innovative Cellular Therapeutics (ICT) | LinkedIn Immunomic Therapeutics Announces Presentation on Nucleic Acid-Based Amy Conrad Glioblastoma Multiforme (GBM) - Immunomic Therapeutics Report this profile . Immunomic Therapeutics Assumes Sponsorship of ATTAC II IND - Duke OTC It is one of the few malignancies for which incidence approximates prevalence, as patients almost always . ROCKVILLE, Md.-- ( BUSINESS WIRE )--Immunomic Therapeutics, Inc., ("ITI"), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based . The work and relationships that Louise has fostered over the years position us for successful meetings in the future and I look forward to contributing meaningfully to the companys future regulatory interactions to further advance ITIs development programs utilizing the innovative and proprietary UNITE technology platform.. It is interesting to note that the emerging market of brain tumor includes budding gene therapies, i.e., Ofranergene obadenovec (VBL Therapeutics) and Ad-RTS-hIL-12 in combination with Veledimex . ITI-1000 is a cell therapy powered by ITIs UNITE platform that is currently being evaluated in a Phase II clinical trial (ATTAC-II) in collaboration with researchers at the University of Florida (Dr. Duane Mitchell) and Duke University (Dr. John Sampson). At ITI, our success is based in great part on our ability to attract and retain the best, creative, talented, motivated and productive employees throughout our organization. Immunomic Therapeutics considers applicants for all positions without regard to race, color, creed, religion, ancestry, national origin, age, gender identity, sex, marital status, sexual orientation, physical or mental disability, use of a guide dog or service animal, military/veteran status, citizenship status, basis of genetic information, or any other group protected by law. Animal Health All. Immunomic Therapeutics, Inc. | 2,335 followers on LinkedIn. ITI-3000 Merkel Cell Carcinoma - pDNA. all maps fatal bullet; who is running for senate in maryland 2022 CONTACT US. We are also collaborating with academic centers and biotechnology companies to study the use of the UNITE platform in cancer types of high mortality, including cases where there are limited treatment options like glioblastoma. In this way, ITIs vaccines (DNA or RNA) have the potential to utilize the bodys natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. CONTACT - MiNA Therapeutics | RNA Activation J Immunol. 1K followers 500+ connections. William Hearl - President & CEO - Immunomic Therapeutics, Inc Melody Carey As a result, a robust T cell response by both CD4+ and CD8+ T cells is expected to drive antitumor activity of this product. 917-322-2571, Internet Explorer presents a security risk. ITI-1000 is a dendritic cell therapy comprised of autologous dendritic cells (DCs) loaded with messenger ribonucleic acid (mRNA) encoding the human Lysosomal Associated Membrane Protein (hLAMP) gene fused in frame to a human Cytomegalovirus (hCMV) matrix protein, pp65 gene (hLAMP:pp65) and subsequently administered with Granulocyte-macrophage colony-stimulating factor (GM-CSF) and Tetanus/diphtheria (Td) toxoid which serve as adjuvants. The oncogenes E6 and E7 in both HPV 16 and HPV 18 strains are well proven to be immunogenic, providing the support to develop this product.ITI-2000, delivered by needle and syringe as a self-amplifying construct, will be indicated for HPV-positive cancers. Immunomic Therapeutics, Inc. | LinkedIn ITI is primarily focused on applying the UNITE platform to oncology, where it could potentially have broad applications, including antigen-derived antibodies as biologics. Immunomic Therapeutics Announces Open Enrollment for RENEW Clinical 15010 Broschart Road Suite 250. Hershey, PA & Rockville, MD and Tokyo, Japan. We know that there are multiple aspects that inform our platform's success. GBM patients white blood cells are removed, matured into dendritic cells and vaccinated against the pp65 viral protein, then returned to the patient. Our Company Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE ), which is designed to utilize the body's natural biochemistry to develop vaccines that generate broad immune responses Read More Our Focus ITI is . We provide a professional and challenging work environment . Founders Sungwuk Kim. Rockville's Immunomic Therapeutics Inc. is on track to go public later this year, after Covid-19 threw a wrench in the vaccine maker's initial timeline. ITI Company: 2020 Immunomic Therapeutics, Inc. All Rights Reserved. View contacts for Immunic Therapeutics to access new leads and connect with decision-makers. The company was founded in 2005 and is based in Lancaster, Pennsylvania. ITI-2000 provides an UNITE platform address for HPV+ cancers. ITIs lysosomal targeting technology is currently being employed in a Phase II clinical trial as a cancer immunotherapy. Stemming from our UNITE Platform, Immunomic Therapeutics has developed a robust and deep pipeline focused on immunotherapeutics with an emphasis in treating and preventing many oncology indications by leveraging specific characteristics of a type of antigen. CFO at Immunomic Therapeutics, Inc. Germantown, Maryland, United States. Evaluate their financials based on Immunomic Therapeutics's post-money valuation and revenue. November 20, 2020-- Immunomic Therapeutics (ITI) and CoImmune Therapeutics have entered into a license agreement for ITI to use CoImmune's proprietary dendritic cell process for certain ITI cell therapy vaccine programs. Immunomic Therapeutics nucleic acid vaccines have the potential to utilize the bodys natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. The primary mechanism of action of ITI-1000 is to generate a T cell-mediated immune response against malignant glial cells expressing the CMV pp65 protein. ITI granted Japanese animal health company, ZENOAQ (Nippon Zenyaku Kogyo Co., Ltd, Koriyama, Japan) an exclusive license to develop and commercialize its investigational DNA vaccine for canine atopic dermatitis and other companion animal allergies. Immunic is a biopharmaceutical company that develops a pipeline of selective oral immunology therapies. Immunomic Therapeutics, Inc. To ensure the most secure and best overall experience on our website, we recommend the latest versions of. See Immunomic Therapeutics funding rounds, investors, investments, exits and more. Immunomic Therapeutics is a development stage biotechnology company that develops lysosomal associated membrane protein-based vaccines. ITI Media: We now have a well-defined process to take things from ideation to in vivo animal proof of concept studies before handing them off to product development. 2020 Immunomic Therapeutics, Inc. All Rights Reserved. January 30, 2015 - Immunomic Therapeutics, Inc. ("Immunomic Therapeutics "), a company developing next generation vaccines based on the LAMP-vax platform, and Astellas Pharma Inc. ("Astellas") today announced they have entered into an exclusive license agreement for Japan to . We are based at the Translation & Innovation Hub that sits on Imperial College London's 23-acre White City Campus development in west . To explore Immunic Therapeutics's full profile, request access. Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal . Chief Scientific Officer (CSO) Immunomic Therapeutics, Inc. Jun 2019 - Present3 years 9 months. Clin Cancer Res. We believe that these early clinical studies may provide a proof of concept for UNITE in cancer, and if successful, set the stage for future studies, including combinations in these tumor types and others. The initial foray into immuno-oncology was undertaken when ITI decided to support the work of Drs. The company believes this approach may harness the bodys immune system to recognize, attack and destroy tumor cells that express CMV, which is over-expressed in GBM. In addition to TH1 response, we also observe antigen specific antibodies indicative of TH2 response further enhancing the anti-tumor potential of this vaccine.ITI-1001 presents an alternative for patients that missed the treatment window for other therapies or that cannot produce enough cells to start cell therapy manufacturing (~30% of patients). IMU-935, a selective inverse agonist of the transcription factor RORt, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barr syndrome. This approach could put UNITE technology at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. Preclinical data is currently being developed to explore whether the UNITE platform may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response.